Projekte
Suche in 1157 Projekten:
1157 Projekt(e)
TEAR und EARLY ALS
01.09.2021Hintergrund der Studie zur Analyse von Tränenflüssigkeit (TEAR-ALS) ist die Identifizierung von Biomarkern. Tränendrüsen haben eine enge anatomische Beziehung zum Hirnstamm, welcher eine zentrale Rolle bei neurodegenerativen Erkrankungen spielt. Ein...
Grundlagenforschung - 01.09.2021 - 31.03.2024
Automatisch geschlossen
Projektleitung: Neuwirth Christoph
Mitarbeiter/innen: Braun Nathalie
BMS CA224-104 Phase 2 Randomized Double-blind Study of Relatlimab plus Nivolumab in Combination with Chemothera-py vs. Nivolumab in Combination with Chemotherapy as First Line Treatment for Participants with Stage IV or Recurrent Non-small Cell Lung Cancer (NSCLC)
30.07.2021Immunotherapy plays substantial role in first line treatment of NSCLC Stage IV. Current standard of care is – depending on PD-L1 expression- anti-PD-(L)1 alone or in combination with PDCT which has demonstrated significant improvements in OS as well...
Klinische Forschung - 30.07.2021 - 31.12.2025
Laufend
CAR T- Cell EBMT Registry data processing framework
30.07.2021
Klinische Forschung - 30.07.2021 - 31.12.2026
Laufend
Projektleitung: Fehr Martin
Mitarbeiter/innen: Breuss Kim, Müller Fiona
Eine Studie zu Relatlimab plus Nivolumab in Kombination mit Chemotherapie vs. Nivolumab in Kombination mit Chemotherapie bei Teilnehmern mit nicht-kleinzelligem Lungenkarzinom (NSCLC) im Stadium IV oder bei einem Wiederauftreten.
30.07.2021Diese Studie besteht aus zwei Hauptteilen. In der Schweiz wurde Teil 1 bereits beendet. In Teil 1 werden verschiedene Dosen Relatlimab zusammen mit Nivolumab und Chemotherapie verabreicht, um sicherzustellen, dass die Prüfpräparat-Kombination bei Pat...
Klinische Forschung - 30.07.2021 - 31.12.2026
Laufend
Projektleitung: Weindler Susanne
Mitarbeiter/innen: Berbic Hong Phuong
MSD MK1308A-004
03.07.2021Phase 2, Multicenter, Clinical Study to Evaluate the Safety and Efficacy of MK-1308A (Coformulated MK-1308/MK-3475) in Combination with Lenvatinib (E7080/MK-7902) in First-line Therapy of Participants with Advanced Hepatocellular Carcinoma
Klinische Forschung - 03.07.2021 - 03.12.2022
Automatisch geschlossen
Projektleitung: Semela David
Mitarbeiter/innen: Stillhard Roman, Bergamin Irina
Immunoproteasome activity as a predictive marker and therapeutic target in hematological malignancies
01.07.2021
Grundlagenforschung - 01.07.2021 - 31.12.2021
Automatisch geschlossen
Projektleitung: Besse Andrej
Mitarbeiter/innen: Kraus Marianne, Besse Lenka
SAKK 15/19 Thoracic radiotherapy plus maintenance Durvalumab after first line Carboplatin and Etoposide plus Durvalumab in extensive-stage disease small cell lung cancer (EDSCLC) A multicenter single arm open label phase il trial
24.06.2021Standard of care for Extensive-Stage Disease (ED) Small Cell Lung Cancer (SCLC) as first-line treatment is 4 to 6 cycles of platinum based chemotherapy (carboplatin or cisplatin) in combination with etoposide. However, the outcome of the disease...
Klinische Forschung - 24.06.2021 - 28.06.2027
Laufend
Projektleitung: Früh Martin
Mitarbeiter/innen: Demmer-Steingruber Ruth, Quinter Janine
ALFA ROMEO
23.06.2021Atrial fibrillation before and after patent foramen ovale closure study This is a prospective, multicenter, single-arm, observational study assessing the incidence, predictors and prognostic impact of AF occurring before (monitoring phase A) or af...
Klinische Forschung - 23.06.2021 - 23.06.2027
Laufend
Projektleitung: Chronis Joannis
Mitarbeiter/innen: Schneider Irene, Vetsch Susanne
SWISS-AF Control Group
17.06.2021Contemporary findings from the ongoing Swiss-AF cohort study (2’415 patients with atrial fibrillation (AF) enrolled, 1’760 patients with available brain imaging) showed that patients with AF have a high burden of cerebral infarcts and other brain les...
Klinische Forschung - 17.06.2021 - 17.06.2025
Laufend
Projektleitung: Ammann Peter
Mitarbeiter/innen: Fink Karin
Assessing a ctDNA and PET-oriented therapy in patients with DLBCL multicenter, open-label, phase II trial
08.06.2021Despite advances in the clinical care of patients with DLBCL and in understanding the biology of this disease, cure rates have remained the same since the introduction of rituximab to CHOP chemotherapy, and RCHOP chemoimmunotherapy remains the standa...
Klinische Forschung - 08.06.2021 - 31.12.2030
Laufend
Projektleitung: Hitz Felicitas
Mitarbeiter/innen: Harder Anja, Quinter Janine
Application of smart sensor insoles for assessment of gait parameters and correlation to patient-reported outcomes in hip arthroplasty patients
01.06.2021Gait parameters like gait velocity, stride length, cadence or load symmetry contribute to a successful outcome after total hip arthroplasty (THA) and can be addressed through targeted physiotherapeutic training programs. Instrumented gait analysis i...
Grundlagenforschung - 01.06.2021 - 30.06.2025
Geplant
Projektleitung: Ladurner Andreas
Mitarbeiter/innen: Giesinger Karlmeinrad
Analysis of the maturation of the peripheral nervous system in neonates, infants and children using high-resolution ultrasound imaging
01.06.2021During early childhood nerve conduction velocity (NCS) increases from 20m/s at the time of birth to almost adult values of 50m/s at two years of age. How this increase in NCS is correlated to the structural maturation of the peripheral nerves is unkn...
Klinische Forschung - 01.06.2021 - 01.06.2023
Automatisch geschlossen
Mitarbeiter/innen: Broser Philip
SAKK 67/20 Open-label single-stage phase 1B study of the new micellar docetaxel compound Docecal in patients with advanced castra-tion-resistant prostate cancer
28.05.2021Background: Docetaxel, a semi-synthetic analogue of paclitaxel, is one of the most widely used human anti-cancer agents. Docetaxel and paclitaxel belong to a group of cytotoxic agents called tax-anes. Docetaxel has been marketed worldwide by Sanofi-...
Klinische Forschung - 28.05.2021 - 31.12.2024
Abgeschlossen
Projektleitung: Fischer Stefanie
Mitarbeiter/innen: Aeschbacher Anette
Pilot study on cognitive and social function measures for early detection of progressive neurocognitive disorders in Switzerland
12.05.2021
Klinische Forschung - 12.05.2021 - 15.09.2022
Abgeschlossen
Projektleitung: Felbecker Ansgar
Profiling of quitting trajectories during smoking cessation attempt (SMOKEPROFILE-Study)
01.05.2021The study hypothesis is twofold. First, we hypothesize that investigating daily tobacco consumption of smokers attempting to quit can be used to characterize clinically relevant quitting trajectories which can be used to predict quitting success. Our...
Grundlagenforschung - 01.05.2021 - 30.12.2023
Automatisch geschlossen
Projektleitung: Baty Florent
Mitarbeiter/innen: Brutsche Martin, Bösch Maximilian, Pohle Susanne
Comparison of the effect of outdoor eccentric versus indoor concentric exercise training on physical capacity and qualityof-life in patients with advanced COPD (DOWNHILL-study)
01.05.2021Patients with chronic obstructive pulmonary disease (COPD) often suffer from cardio-pulmonary limitations, which makes them avoid exercise training. However, exercise training is explicitly recommended for COPD patients as physical activity (PA) is k...
Grundlagenforschung - 01.05.2021 - 30.04.2025
Laufend
Projektleitung: Bösch Maximilian
Mitarbeiter/innen: Baty Florent, Brutsche Martin, Benz Gabriel
Response to COVID-19 vaccination and COVID-19 infections after vaccination in patients with haematological malignancies
01.05.2021The prevalence and mortality of COVID-19 are higher in patients with haematological malignancies (HM) compared to the general population (Vijenthira et al. 2020). Two SARS-CoV-2 messenger RNA (mRNA) vaccines have been approved by Swissmedic, both are...
Klinische Forschung - 01.05.2021 - 01.10.2022
Abgeschlossen
Projektleitung: Silzle Tobias
Mitarbeiter/innen: Fischer Stefanie, Kahlert Christian, Albrich Werner
An Open-Label, Multicenter, Phase 1b/2 Study of the Safety and Efficacy of KRT-232 in Combination with Acalabrutinib in Subjects with Relapsed/Refractory Dif-fuse Large B-cell Lymphoma or Relapsed/Refractory Chronic Lymphocytic Leukemia
22.04.2021Aclabrutinib wird in Kombination mit KRT 232 bei R/R CLL und de novo R/R DLBCL jeweils TP 53 WT und BTK naiv eingesetzt. Initial Dosisescalations-stufe (Ib), anschlies-send Phase-II mit RP2D. Primärer Endpunkt: Dosisfin-dung/ Safety ; Efficacy in Ph...
Klinische Forschung - 22.04.2021 - 20.05.2030
Abgeschlossen
Projektleitung: Hess Dagmar
Mitarbeiter/innen: Scherrer Julia, Müller Fiona
Bayer 20324
14.04.2021TRK fusion cancer is rare but presents as a variety of solid tumors. Larotrectinib is a highly selective TRK inhibitor that, in a pooled analysis of patients in phase 1/2 clinical trials, demonstrated an effective and sustained response in the majori...
Klinische Forschung - 14.04.2021 - 21.04.2021
Automatisch geschlossen
A multicenter, non-randomized, open-label phase 1b study to determine the maximum tolerated and recommended phase 2 dose of the ATR Inhibitor BAY 1895344 in combination with pembrolizumab and characterize its safety, tolerability, pharmacokinetics and preliminiary anti-tumor activity in patients with advanced solid tumors
14.04.2021BAY-1895344 und Pembrolizumab bei ausgewählten Tumoren mit genetischen Alterationen von ATM.
Klinische Forschung - 14.04.2021 - 21.02.2022
Automatisch geschlossen
Projektleitung: Jörger Markus